NASDAQ:OPK - Opko Health Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Opko Health Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.38 -0.01 (-0.72 %) (As of 02/26/2020 04:00 PM ET) Add Compare Today's Range$1.37Now: $1.38▼$1.4350-Day Range$1.39MA: $1.55▼$1.7352-Week Range$1.33Now: $1.38▼$2.86Volume4.20 million shsAverage Volume3.70 million shsMarket Capitalization$918.53 millionP/E RatioN/ADividend YieldN/ABeta2.39 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:OPK Previous Symbol CUSIP68375N10 CIK944809 Webhttp://www.opko.com/ Phone305-575-4100Debt Debt-to-Equity Ratio0.14 Current Ratio1.08 Quick Ratio0.90Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$990.30 million Price / Sales0.93 Cash FlowN/A Price / Cash FlowN/A Book Value$3.06 per share Price / Book0.45Profitability EPS (Most Recent Fiscal Year)($0.25) Net Income$-153,040,000.00 Net Margins-30.98% Return on Equity-14.42% Return on Assets-10.10%Miscellaneous Employees5,690 Outstanding Shares665,601,000Market Cap$918.53 million Next Earnings Date2/26/2020 (Confirmed) OptionableOptionable Receive OPK News and Ratings via Email Sign-up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:OPK Rates by TradingView Opko Health (NASDAQ:OPK) Frequently Asked Questions What is Opko Health's stock symbol? Opko Health trades on the NASDAQ under the ticker symbol "OPK." How were Opko Health's earnings last quarter? Opko Health Inc. (NASDAQ:OPK) released its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.09) by $0.02. The biotechnology company earned $228.80 million during the quarter, compared to the consensus estimate of $225.40 million. Opko Health had a negative net margin of 30.98% and a negative return on equity of 14.42%. The firm's revenue was down 8.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.05) earnings per share. View Opko Health's Earnings History. When is Opko Health's next earnings date? Opko Health is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Opko Health. What price target have analysts set for OPK? 2 Wall Street analysts have issued 12-month price objectives for Opko Health's stock. Their forecasts range from $2.50 to $4.00. On average, they expect Opko Health's stock price to reach $3.25 in the next year. This suggests a possible upside of 135.5% from the stock's current price. View Analyst Price Targets for Opko Health. What is the consensus analysts' recommendation for Opko Health? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opko Health. What are Wall Street analysts saying about Opko Health stock? Here are some recent quotes from research analysts about Opko Health stock: 1. According to Zacks Investment Research, "OPKO Health has gained significantly from RAYALDEE contribution in recent times. Further, OPKO Health’s utilization of the 4Kscore remains strong, with nearly 18,800 tests registered in the second quarter. These apart, the company’s clinical development programs look promising with a robust pipeline of candidates. Several metabolic and endocrinology programs that are underway should provide OPKO Health a competitive advantage. However, the company’s gross margin is under pressure at the moment. Moreover, the company faces cutthroat competition in the MedTech space. Sluggishness in the Services revenue segment remains a concern. OPKO Health underperformed its industry in a year’s time." (10/18/2019) 2. Barrington Research analysts commented, "We continue to rate OPK shares an OUTPERFORM and our price target remains $4. That said, if the company were to receive a strong data readout from its Phase III trial for hGH‐CTP within the next few months, we suspect that shares would rally meaningfully from current levels and that investor sentiment could swing positive for the first time in over four years. We arrive at our price target via a DCF methodology. It is important to note that the company still has many “shots on goal” within its current commercial portfolio and product development pipeline." (9/12/2019) Has Opko Health been receiving favorable news coverage? News coverage about OPK stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Opko Health earned a news impact score of -1.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Opko Health. Are investors shorting Opko Health? Opko Health saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 80,770,000 shares, an increase of 5.5% from the December 31st total of 76,560,000 shares. Based on an average daily trading volume, of 5,380,000 shares, the days-to-cover ratio is presently 15.0 days. Currently, 20.2% of the company's stock are sold short. View Opko Health's Current Options Chain. Who are some of Opko Health's key competitors? Some companies that are related to Opko Health include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Opko Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Opko Health investors own include TherapeuticsMD (TXMD), bluebird bio (BLUE), Micron Technology (MU), Gray Television (GTN), Allergan (AGN), Gilead Sciences (GILD), NVIDIA (NVDA), Novavax (NVAX), AT&T (T) and Bausch Health Companies (BHC). Who are Opko Health's key executives? Opko Health's management team includes the folowing people: Dr. Phillip Frost, Chairman & CEO (Age 83)Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 72)Mr. Adam E. Logal, Sr. VP, CFO, Chief Accounting Officer & Treasurer (Age 41)Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 59)Ms. Kate Inman, Gen. Counsel & Sec. (Age 46) Who are Opko Health's major shareholders? Opko Health's stock is owned by many different of retail and institutional investors. Top institutional shareholders include State Street Corp (2.69%), Geode Capital Management LLC (0.90%), Oracle Investment Management Inc. (0.66%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (0.45%), Marshall Wace LLP (0.38%) and Farallon Capital Management LLC (0.38%). Company insiders that own Opko Health stock include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Institutional Ownership Trends for Opko Health. Which major investors are selling Opko Health stock? OPK stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Bank of Montreal Can, X Square Capital LLC, Connor Clark & Lunn Investment Management Ltd., Rafferty Asset Management LLC, Cito Capital Group LLC, Prudential Financial Inc. and New York State Common Retirement Fund. View Insider Buying and Selling for Opko Health. Which major investors are buying Opko Health stock? OPK stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Marshall Wace LLP, Farallon Capital Management LLC, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Geode Capital Management LLC and Jane Street Group LLC. Company insiders that have bought Opko Health stock in the last two years include Adam Logal, Jane Ph D Hsiao, John A Paganelli, Phillip Md Et Al Frost, Richard C Pfenniger Jr, Robert Scott Fishel and Steven D Rubin. View Insider Buying and Selling for Opko Health. How do I buy shares of Opko Health? Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Opko Health's stock price today? One share of OPK stock can currently be purchased for approximately $1.38. How big of a company is Opko Health? Opko Health has a market capitalization of $918.53 million and generates $990.30 million in revenue each year. The biotechnology company earns $-153,040,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Opko Health employs 5,690 workers across the globe.View Additional Information About Opko Health. What is Opko Health's official website? The official website for Opko Health is http://www.opko.com/. How can I contact Opko Health? Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected] MarketBeat Community Rating for Opko Health (NASDAQ OPK)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 444 (Vote Outperform)Underperform Votes: 433 (Vote Underperform)Total Votes: 877MarketBeat's community ratings are surveys of what our community members think about Opko Health and other stocks. Vote "Outperform" if you believe OPK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/26/2020 by MarketBeat.com StaffFeatured Article: What causes a recession?
